Opaleye Management’s Karyopharm Therapeutics KPTI Stock Holding History

Opaleye Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-930,000	Closed	-$6.84M	–	59
2025 Q4	$6.84M	Buy	+930,000	New	+$5.69M	0.9%	26
2024 Q3	–	Sell	-95,000	Closed	-$1.24M	–	50
2024 Q2	$1.24M	Buy	+95,000	New	+$1.57M	0.28%	44
2023 Q3	–	Sell	-119,000	Closed	-$3.2M	–	47
2023 Q2	$3.2M	Sell	119,000 -68,387	-36%	-$2.95M	0.76%	32
2023 Q1	$10.9M	Buy	187,387 +106,931	+133%	+$5.28M	3.27%	6
2022 Q4	$4.28M	Buy	+80,456	New	+$5.58M	1.49%	22
2017 Q2	–	Sell	-4,000	Closed	-$770K	–	45
2017 Q1	$770K	Buy	+4,000	New	+$642K	0.38%	39
2014 Q3	–	Sell	-2,000	Closed	-$1.4M	–	31
2014 Q2	$1.4M	Buy	+2,000	New	+$931K	1.2%	20

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Opaleye Management's KPTI Position: Q1 2026 in Review

Opaleye Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 930,000 shares — an estimated $6.84M sold.

Opaleye Management first reported a position in KPTI in Q2 2014 and held it in 7 quarters. The position peaked at $10.9M in Q1 2023. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Opaleye Management reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
Opaleye Management sold 930,000 Karyopharm Therapeutics shares in Q1 2026, an estimated $6.84M.
Opaleye Management first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 7 quarters.
Opaleye Management's Karyopharm Therapeutics position peaked at $10.9M in Q1 2023.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.